Gan & Lee Pharmaceuticals (SHA:603087) dosed the first subject for the phase I clinical trial of its GLR1023 injection, according to a Shanghai Stock Exchange filing on Thursday.
The drug, marketed as Cosentyx, is used to treat moderate to severe plaque psoriasis in adults. The trial aims to compare the similarity of the main pharmacokinetic parameters, immunogenicity and safety between a single subcutaneous injection of GLR1023 injection and secukinumab injection in healthy adult male subjects in China.
The Chinese pharmaceutical company invested 64.4 million yuan into the research and development of the drug, the filing said.
Shares of the company rose more than 2% in recent trade.
Price (RMB): ¥52.15, Change: ¥+1.3, Percent Change: +2.48%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.